PLoS ONE:咖啡因和特定基因相互作用可保护机体抵御帕金森疾病

2014-07-15 佚名 不详

近日,刊登在国际杂志PLoS One上的一篇研究论文中,来自瑞典LinKoping大学的研究人员通过研究发现,一种特殊的遗传突变或许可以保护个体抵御帕金森疾病,尤其是那些大量饮用咖啡的个体,其更不抑易患帕金森疾病。 在疾病的出现过程中遗传因素和环境因子会发生相互作用,而当前研究者的重点则是对增加感染性疾病风险的基因进行鉴别,但是往往存在一定的遗传突变和环境因子,其二者可以保护机体抵御特定疾病的发

近日,刊登在国际杂志PLoS One上的一篇研究论文中,来自瑞典LinKoping大学的研究人员通过研究发现,一种特殊的遗传突变或许可以保护个体抵御帕金森疾病,尤其是那些大量饮用咖啡的个体,其更不抑易患帕金森疾病。

在疾病的出现过程中遗传因素和环境因子会发生相互作用,而当前研究者的重点则是对增加感染性疾病风险的基因进行鉴别,但是往往存在一定的遗传突变和环境因子,其二者可以保护机体抵御特定疾病的发生。

神经变性疾病比如帕金森疾病,其发病机制非常复杂,在其发病过程中涉及个体的遗传因素以及外部的环境因子;这项研究中研究人员对百万遗传畸形患者进行研究,发现了一种名为GRIN2A基因的突变体,其或许是保护机体抵御帕金森疾病的保护性因子,该基因表达的蛋白在许多神经变性疾病发病过程中扮演着重要作用。

文章中,研究者对瑞典东南部的两个县进行了帕金森疾病患者的流行病学调查研究,同时检测了此前的一种保护性因子-咖啡因和基因GRIN2A的遗传突变体的结合对帕金森疾病带来的效应,研究显示,两种因素结合起来可明显降低个体发展为帕金森疾病的风险。

这项研究从分子水平上解释了增加咖啡因摄入对个体患帕金森疾病所带来的保护性效应,咖啡因可以结合多巴胺受体,而多巴胺受体可以调节钙质流入细胞,多巴胺作为机体的一部分“奖赏系统”,其可以和咖啡因之间相互作用;据推测,特定遗传突变的个体并不会通过喝一杯咖啡得到所谓的“奖赏”,因此这样的个体并不能得到和其它个体一样的保护性效应。

原始出处

Yamada-Fowler N1, Fredrikson M2, Söderkvist P1.Caffeine Interaction with Glutamate Receptor Gene GRIN2A: Parkinson's Disease in Swedish Population.PLoS One. 2014 Jun 10;.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909176, encodeId=63e419091e6c1, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Mar 09 19:16:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789604, encodeId=6f661e8960475, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jan 24 08:16:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263918, encodeId=84601263918e0, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406642, encodeId=f8ee14066423f, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471499, encodeId=29bc14e1499de, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909176, encodeId=63e419091e6c1, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Mar 09 19:16:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789604, encodeId=6f661e8960475, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jan 24 08:16:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263918, encodeId=84601263918e0, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406642, encodeId=f8ee14066423f, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471499, encodeId=29bc14e1499de, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909176, encodeId=63e419091e6c1, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Mar 09 19:16:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789604, encodeId=6f661e8960475, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jan 24 08:16:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263918, encodeId=84601263918e0, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406642, encodeId=f8ee14066423f, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471499, encodeId=29bc14e1499de, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1909176, encodeId=63e419091e6c1, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Mar 09 19:16:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789604, encodeId=6f661e8960475, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jan 24 08:16:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263918, encodeId=84601263918e0, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406642, encodeId=f8ee14066423f, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471499, encodeId=29bc14e1499de, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1909176, encodeId=63e419091e6c1, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Mar 09 19:16:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789604, encodeId=6f661e8960475, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jan 24 08:16:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263918, encodeId=84601263918e0, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406642, encodeId=f8ee14066423f, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471499, encodeId=29bc14e1499de, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Thu Jul 17 00:16:00 CST 2014, time=2014-07-17, status=1, ipAttribution=)]
    2014-07-17 ylz8405

相关资讯

Stroke:含咖啡因药与出血性卒中危险增加相关

  韩国一项研究表明,应用含有咖啡因的药物(CCM)与出血性卒中(HS)危险增加相关,包括蛛网膜下腔出血和脑出血。论文6月6日在线发表于《卒中》(Stroke)杂志。   该多中心病例对照研究共纳入940例年龄在30—84之间无卒中病史的非创伤性急性HS患者,以与之年龄和性别相匹配的940社区居民和住院者作为对照组。获取各组患者卒中首发时间及此时间之前的14天患者的药物应用信息。以首发卒中前或卒

JCEM:咖啡因可抑制PTH分泌

咖啡因作为一种大量消费的精神活性物质出现在我们日常饮品中。体内和体外的独立研究报道咖啡因消耗量与低骨矿密度和尿钙丢失、以及骨发育受损有关。钙(Ca2+)、维生素D和甲状旁腺激素(PTH)是骨重建的关键调节因子。为了探讨咖啡因与甲状旁腺功能之间的可能关系,来自瑞典卡罗林斯卡大学医院的Ming Lu教授及其团队进行了一项研究,该研究发现咖啡因可抑制PTH分泌。该研究结果在线发表在2013年6月20日的

孕妇喝咖啡负面影响争论再起

当一名女性成为准妈妈的那一刻,向医生首先咨询的问题中一定包括:我可以继续喝咖啡或含咖啡因的碳酸饮料吗?医生通常会说孕妇每天喝咖啡的量应控制在一至两杯,这一建议和2010年得出的一项结论一致:适度咖啡因摄入量不会增加早产或流产的风险,也不会损害胎儿发育。 但是一项新的小鼠实验提供了一个有争议的结论:更大剂量的咖啡因摄入会损伤记忆力,增加癫痫发作的风险。 尽管该研究的作者和其他人迅

Hepatology:适量摄入咖啡因或能防治脂肪肝

咖啡或茶中含有咖啡因,很多人知道它可以缓解疲劳、驱走睡意。最新研究表明,适度摄入咖啡因还可能降低一类常见脂肪肝的风险。 该研究由美国杜克大学医学院等机构进行。通过细胞培养实验和以高脂膳食喂养的小鼠进行动物实验,研究人员发现,咖啡和茶中所含的咖啡因能刺激肝细胞内堆积的脂类新陈代谢,并有效降低小鼠的脂肪肝程度。【原文下载】 最终结果表明,人体如果每天摄入四杯左右的咖啡或茶,其所含的咖啡因对防治非酒

AM J EPIDEMIOL:含咖啡因的咖啡可降低口腔癌风险

  美国癌症协会近期一项研究显示,含咖啡因的咖啡与口腔癌/咽喉癌的死亡率之间存在明显的逆相关性。研究人员介绍称,每天饮用含咖啡因的咖啡超过4杯可使人们因口腔癌而死亡的风险比很少喝或不喝咖啡的人们的风险低将近一半。这一研究结果被刊登在《美国流行病学杂志》网站上。研究人员表示,相关作用的生物学机制有待更多的研究来进一步证实。   先前的一些流行病学研究已经表明,咖啡可使口腔癌/咽喉癌的风险降低。为了

PLoS One:研究发现咖啡因减缓老鼠大脑发育

人类和其他哺乳动物在青春期表现出特别密集的睡眠模式。大脑在这一时期也成熟的最快。但是,一项研究发现当青春期老鼠给予咖啡因后,它们大脑成熟过程被延迟。 在过去的30年中,儿童和年轻成人平均咖啡因的消耗增加70%多,并且这个“崛起”还远没有结束的倾向。咖啡因饮料的发展并不是每个人都感到高兴。有些人担心可能对年轻消费者引起健康风险。 对于这一辩论,研究人员现在增加了新